Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acromegaly

S Melmed1

  • 1Division of Endocrinology and Metabolism, Cedars-Sinai Research Institute, UCLA School of Medicine 90048-1865, USA.

Metabolism: Clinical and Experimental
|August 1, 1996
PubMed
Summary
This summary is machine-generated.

Acromegaly involves pituitary defects causing high growth hormone (GH) and insulin-like growth factor-1 (IGF-1). Octreotide treatment effectively normalizes these levels and reduces tumor size in many patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consensus and controversies about diagnosing GH deficiency: a Delphi survey by the GH research society.

Pituitary·2025
Same author

Medical management pathways for Cushing's disease in pituitary tumors centers of excellence (PTCOEs).

Pituitary·2025
Same author

Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE).

Pituitary·2024
Same author

Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers.

Pituitary·2023
Same author

Expression of leukemia inhibitory factor in craniopharyngioma.

Endocrine pathology·2016
Same author

Sagit©: A Novel Clinician-Reported Outcome for Managing Acromegaly in Clinical Practice.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same journal

Ablation of microglial estrogen receptor alpha predisposes male mice to diet-induced obesity.

Metabolism: clinical and experimental·2026
Same journal

Pathophysiology-based subtypes of individuals at high-risk of type 2 diabetes: multi-omics profiles and lifestyle differences across subtypes.

Metabolism: clinical and experimental·2026
Same journal

A thermosensitive TET-Parkin epigenetic axis couples mitochondrial quality control to adaptive thermogenesis in adipose tissue.

Metabolism: clinical and experimental·2026
Same journal

Raffinose targets the NQO1/NF-κB axis to attenuate DON-driven microglial activation and neuroinflammation via metabolic reprogramming.

Metabolism: clinical and experimental·2026
Same journal

Endothelial NPR-C promotes insulin resistance via Caveolin-1-mediated insulin transcytosis.

Metabolism: clinical and experimental·2026
Same journal

Macrophage-enriched GPR91 aggravates acute liver injury by inhibiting efferocytosis via the AC/cAMP/PPARγ pathway.

Metabolism: clinical and experimental·2026
See all related articles

Area of Science:

  • Endocrinology
  • Pituitary Disorders
  • Oncology

Background:

  • Acromegaly stems from intrinsic pituitary defects, leading to elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1).
  • These hormonal imbalances significantly impact cardiovascular, respiratory, and neoplastic cell proliferation.
  • Current treatments like surgery and radiation have limited success rates (under 60%) and associated side effects.

Purpose of the Study:

  • To evaluate the efficacy of octreotide in managing acromegaly.
  • To assess the impact of octreotide on hormonal levels, tumor size, and clinical manifestations.
  • To highlight the role of GH normalization in improving patient outcomes.

Main Methods:

  • Review of existing literature on acromegaly treatment.

Related Experiment Videos

  • Analysis of octreotide's effects on growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels.
  • Assessment of octreotide's impact on tumor size and patient-reported outcomes.

    • Main Results:

    • Octreotide normalizes GH and IGF-1 levels in up to 60% of patients.
    • Tumor size reduction is observed in up to 50% of patients treated with octreotide.
    • GH levels are attenuated in over 90% of patients, suggesting significant therapeutic benefit.

    Conclusions:

    • Octreotide represents a significant advancement in acromegaly management.
    • Normalization of GH levels through octreotide may improve survival rates.
    • Further research is needed to clarify optimal outcome measures and the long-term role of octreotide.